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Abstract 
It is known that ceftriaxone administration
is  associated  with  biliary  pseudolithiasis,
although the development of urolithiasis has
been rarely reported. We encountered a young
male with bacterial meningitis complicated by
urinary precipitates composed of ceftriaxone-
calcium salt which is confirmed by high-per-
formance liquid chromatography. This patient
suggested  that  ceftriaxone  significantly
increased urinary excretion of calcium, which
may be linked to ceftriaxone-related urolithia-
sis  or  sludge.  It  is  therefore  worthwhile  to
monitor the levels of urinary calcium to creati-
nine ratio in patients on ceftriaxone, as they
may  be  at  greater  risk  for  developing  large
stones and renal damage. 
Introduction
Ceftriaxone  is  a  third  generation
cephalosporin, and is a broad spectrum antibi-
otic with a long plasma half-life that is widely
used to treat infections during childhood.1 It is
well  known  that  ceftriaxone  administration
has been associated with biliary pseudolithia-
sis in children.2,3 Although the development of
urolithiasis or sludge in the urinary tract has
been thought to be rare,1,4 recent observations
have  revealed  its  prevalence  is  higher  than
previously  thought.5,6 Despite  several  trials,
the mechanism(s) underlying the formation of
ceftriaxone-associated  urolithiasis  remain
unclear.5,6
We here report a young male with bacterial
meningitis complicated by urinary precipitates
composed of ceftriaxone-calcium salt. 
Case Report
A 1-year-old male was admitted to Nakano
Children’s Hospital, Osaka, Japan with fever
and convulsions on October 16, 2008. He had
previously been in good health. During a phys-
ical examination, it was found that his weight
was 10.6 kg (+1 SD); height, 74 cm (-0.5SD);
pulse rate, 150/min; fever, 39.1°C; he was con-
scious;  and  no  neck  stiffness  was  detected.
From these findings, the diagnosis of complex
febrile seizures was made. However, disturbed
consciousness and a stiff neck which devel-
oped on the following day prompted us to exam
his  cerebrospinal  fluid.  His  leukocyte  count
was  2914/mm3 (84%  neutrophil  leukocyte);
protein,  132  mg/dL;  glucose,  5  mg/dL;  and
simultaneous serum glucose, 119 mg/dL. Gram
negative bacilli were detected on cerebrospinal
fluid Gram staining. Therefore, a provisional
diagnosis  of  acute  bacterial  meningitis  was
made. As shown in Figure 1, both ceftriaxone
(120  mg/kg  per  day)  and  meropenem  (120
mg/kg per day) were administered in two equal
intravenous doses over 60 min. Adjunctive dex-
amethasone  was  also  given  intravenously
every 6 hours at a dose of 0.15 mg/kg for 4 days.
Haemophilus  influenzae tybe  b  grew  on
cererospinal fluid culture and hemoculture. 
On the 13th day of ceftriaxone therapy, the
patient  produced  white  turbid  urine  (Figure
2). However, he did not complain of abdominal
pain, there was no dysuria, and his physical
examination  was  unremarkable.  Abdominal
ultrasonography  revealed  no  abnormal  find-
ings. While his serum calcium level was nor-
mal (9.6 mg/dL), his urinary calcium to creati-
nine ratio (uCa/Cr) was as high at 0.97 (nor-
mal for age: 0.60).7
Based on these findings, we considered that
the white turbid urine was ceftriaxone-calci-
um  precipitates  caused  by  the  administered
ceftriaxone,  which  was  later  confirmed  by
high-performance  liquid  chromatography.
Therefore, ceftriaxone therapy was discontin-
ued.  After  discontinuation,  no  further  white
turbidity  of  the  urine  was  noted,  and  the
uCa/Cr gradually normalized in parallel with
the  recovery  from  bacterial  meningitis,  as
shown in Figure 1. The patient was discharged
without any sequelae on November 20th.
Discussion
Ceftriaxone is primarily eliminated by the
kidneys, although in individual patients up to
65% may be excreted unmetabolized into the
bile.1 As an anion, ceftriaxone readily forms an
insoluble salt with calcium in a 1:1 molar ratio
that is capable of precipitation once the solu-
bility of the salt is exceeded.8 These biochemi-
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Figure 1. The clinical course of the index case with bacterial meningitis.The solid line
and dashed line denote the body temperature and urinary calcium excretion, respective-
ly. uCa/Cr, urinary calcium to creatinine ratio; DEXA, dexamethasone. [Pediatric Reports 2012; 4:e14] [page 53]
cal  characteristics  of  ceftriaxone  treatment
frequently cause biliary sludge or pseudolithi-
asis, and are a well-known side effect in chil-
dren.2,3 This complication is characterized by
asymptomatic biliary changes developing after
2-16  days  of  treatment  and  is  reversible  in
most cases.3,4,9 In contrast to the knowledge
about  the  side  effect  of  psuedolithiasis,  the
epidemiology and pathophysiology of the for-
mation of ceftriaxone-associated nephrolithia-
sis is poorly understood, although its incidence
has been postulated to be higher than previ-
ously thought and it appears that stones can
form in the same way in the renal collecting
system as in hepato-biliary system. However,
most cases of ceftriaxone-induced urolithiasis
and/or  sludge  have  occurred  in  association
with  higher  doses  (greater  than  100  mg/kg
daily) during extended treatment periods or in
the presence of predisposing risk factors for
urinary calculi.1,6 A recent study based on the
findings of the post-treatment ultrasonography
disclosed that 1.4-7.8% of patients had devel-
oped small sized renal calculi while on ceftri-
axone,5,6 although Stojanovic et al. stated that
there  were  only  10  cases  of  ceftriaxone-
induced  nephrolithiasis  in  children  reported
as of 2009.10The precise mechanism(s) under-
lying the development of ceftriaxone-induced
nephroli  thiasis or sludge are largely unknown,
while our case suggests that ceftriaxone treat-
ment may increase the excretion of calcium
into the urine leading to the subsequent pre-
cipitation of ceftriaxone with calcium. 
In conclusion, we should have high index of
suspicion  for  urolithiasis  and  monitor  the
uCa/Cr of patients on high-dose and long-term
ceftriaxone  treatment,  as  these  individuals
may  be  at  greater  risk  for  large  stones  and
renal damage.
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Case Report
Figure 2. A photograph of the white turbid urine excreted after 13 days of ceftriaxone
therapy. The urinary crystalline precipitates shown were confirmed to be ceftriaxone-cal-
cium precipitates. The subject’s serum calcium level was normal (9.6 mg/dL), while his
urinary calcium to creatinine ratio was high at 0.97 (normal for age: 0.603). A, distilled
water for contrast; B, patient’s urine.